Research groups
Matteo Vecellio
PhD
Versus Arthritis Career Development Fellow/Junior PI
RUNX3 regulation in Ankylosing Spondylitis
Ankylosing Spondylitis (AS) is an inflammatory arthritis with numerous robust genetic associations.
The goal of the group is to investigate the epigenetic mechanisms by which RUNX3 gene contribute to AS, deciphering how RUNX3 genetic variants (SNPs) alter transcriptional regulation and affect CD8+ T-cell compartment. We aim to assess the impact of disrupted transcriptional regulation for AS patients and gain new insight into disease pathogenesis.
I joined the Lab of Professor Wordsworth at NDORMS, in June 2013. Previously, I received my PhD degree in Translational and Molecular Medicine in 2012 from the University of Milan – Bicocca (Italy). Soon after my Ph.D I spent one year at the Goethe University in Frankfurt-am-Main (Germany), carrying on the work started during the Ph.D period focused on the epigenetic regulation of human cardiac mesenchymal stromal cells.
I've been awarded in 2017 with a 5 years Arthritis Research UK Career Development Fellowship. Our recent work has been recognized with the Garrod Award 2021- Excellence in Rheumatology Research from the British Society of Rheumatology
Recent publications
-
Advanced genomics and clinical phenotypes in psoriatic arthritis
Journal article
Vecellio M. et al, (2022), Seminars in immunology, 101665 - 101665
-
Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases.
Journal article
De Santis M. et al, (2022), Vaccines (basel), 10
-
2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations.
Journal article
Armstrong AW. et al, (2022), J rheumatol
-
The Conundrum of Psoriatic Arthritis: a Pathogenetic and Clinical Pattern at the Midpoint of Autoinflammation and Autoimmunity.
Journal article
Scrivo R. et al, (2022), Clin rev allergy immunol
-
Antigen Reactivity and Clinical Significance of Autoantibodies Directed Against the Pyruvate Dehydrogenase Antigen Complex in Patients With Connective Tissue Disease.
Journal article
Ceribelli A. et al, (2022), Frontiers in immunology, 13